Is there a problem with tests for HER2-positivity?

Abstract

▪ The data for the use of trastuzumab in women with HER2-positive breast cancer are resoundingly convincing. But now, according to presentations at the meeting, it looks like women with HER2-negative tumours could also benefit from the drug.